BI-836826 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Unspecified Respiratory Disorders. According to GlobalData, Phase I drugs for Unspecified Respiratory Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BI-836826 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BI-836826 overview
BI-836826 is under development for the treatment of unspecified respiratory disorders. The drug candidate is administered as an intravenous infusion. It is an anti-CD37 monoclonal antibody. The drug candidate is developed based on XmAb technology and cytotoxic Fc domain technology. BI836826 improves antibody-dependent cellular cytotoxicity (ADCC) by replacing two amino acids in the Fc region to increase binding affinity to FcyRIIIa. The drug candidate was also under development for the treatment of relapsed or refractory chronic lymphocytic leukaemia and relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma, indolent non-Hodgkin lymphoma of B cell origin, diffuse large B-cell lymphoma and follicular lymphoma.
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers an array of products including human diseases, animal health care products, and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases, among others. It also offers animal healthcare products for swine, ruminant, poultry, horses, and pets, among others. Boehringer is headquartered in Ingelheim am Rhein,Rhineland-Palatinate, Germany.
For a complete picture of BI-836826’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
